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estimating the frequency of Single 
point Driver Mutations across 
common Solid tumours
Madeleine Darbyshire1, Zachary du toit2, Mark f. Rogers1, tom R. Gaunt  3 & colin campbell1
for cancers, such as common solid tumours, variants in the genome give a selective growth advantage 
to certain cells. it has recently been argued that the mean count of coding single nucleotide variants 
acting as disease-drivers in common solid tumours is frequently small in size, but significantly variable 
by cancer type (hypermutation is excluded from this study). in this paper we investigate this proposal 
through the use of integrative machine-learning-based classifiers we have proposed recently for 
predicting the disease-driver status of single nucleotide variants (SnVs) in the human cancer genome. 
We find that predicted driver counts are compatible with this proposal, have similar variabilities by 
cancer type and, to a certain extent, the drivers are identifiable by these machine learning methods. 
We further discuss predicted driver counts stratified by stage of disease and driver counts in non-coding 
regions of the cancer genome, in addition to driver-genes.
For common solid tumours, a number of variants in the coding regions of the human cancer genome can act 
as disease-drivers. Approximately, 95% of these variants are single-base substitutions with 90.7% resulting in 
missense change, 7.6% resulting in nonsense alteration, and 1.7% as alterations in regions adjacent to start and 
stop codons1. However, though there may be many genomic positions where variants can act as disease-drivers, 
an individual clone would only have a small subset of these. There have been various attempts to estimate the 
mean number of driver mutations in common solid tumours. Assuming mutation rates are constant throughout 
life, classic studies based on the relationship between age and cancer incidence led Nordling2 and Armitage and 
Doll3 to suggest approximately six or seven sequential mutational events. Alternative arguments have similarly 
suggested a limited number of driver mutations4. For example, Tomasetti et al.5 argued for only a few sequential 
mutations in a study of lung and colorectal cancer. Using observations based on rates of non-synonymous and 
synonymous base substitutions, Martincorena et al.6 have recently argued that the number of coding substitutions 
that are driver mutations is quite small, on average about 4 per tumour, across common solid tumours. They argue 
that tumour types can vary significantly from this average, from less than 1 for thyroid and testicular tumours, 
to more than 10 in coding regions for endometrial and colorectal tumours6. An exception to this picture is the 
high mutation count which can stem from alterations to the proofreading domains of DNA polymerases POLE 
and POLD1, leading to hypermutation. The basis of their model is the normalized ratio of non-synonymous to 
synonymous mutations (dN/dS) with the assumption that the large majority of synonymous mutations are neu-
tral as disease-drivers, and thus can act as a proxy for the underlying null distribution of neutral variation. Since 
it is based on dN/dS, the model is restricted to coding regions. As reported by the authors6 estimation from dN/
dS can be subject to bias affecting estimation. For example, it is sensitive to mislabelling of germline as somatic 
or vice versa, leading to downward or upward estimation bias respectively. Also, dN/dS is not an approach which 
lends itself readily to test accuracy estimation on independent unseen data, which is a standard validation step for 
the machine learning based methods we now discuss. However, the method proposed by Martincorena et al.6 is a 
helpful comparator model in the discussion below.
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Materials and Methods
In recent years a number of methods have been developed for predicting the pathogenic impact of variants in 
both the coding and non-coding regions of the human genome. For example, in Shihab et al.7 and Rogers et al.8  
we developed such predictors based on pathogenic disease-driver single nucleotide variants (SNVs) from the 
Human Gene Mutation Database (HGMD9) and assumed neutral variants from the 1,000 Genomes Project 
Consortium (1000 G10). A variety of similar predictors have been proposed11–16. Catalogues covering documented 
instances of disease-traits associated with single nucleotide variants, across non-cancer diseases, indicate that 
approximately 90% of these are located in non-coding regions of the human genome17 and our previous tools 
predict a large proportion of disease-driver variants in non-coding regions in consequence. In Rogers et al.18 we 
proposed CScape, a method for predicting the disease-driver status of single nucleotide variants in the coding 
and non-coding regions of the human cancer genome (the method is more fully described in Supplementary 
Section 1). The pathogenic (positive) examples were constructed from somatic single point mutations from the 
COSMIC database19 and the neutral (negative) examples were constructed using SNVs from the 1000 Genomes 
Project10. Henceforth we refer to these types of disease-driver positives as SNV-drivers.
CScape uses integrative binary classification methodology from machine learning (Supplementary Section 1). 
It was not trained on, and does not predict on, mitochondrial or allosomal (X and Y) chromosomes since these 
yield fewer examples of drivers and are functionally different from autosomes. The allosomes have evolutionary 
characteristics (e.g. mutation rates) distinct from autosomal chromosomes, potentially impacting any features 
influenced by mutation rates, such as the sequence conservation scores used (see Supplementary Section 1). In 
addition, the mutational burden on chromosome X could be different between males and females suggesting 
development of a specialist predictor sensitive to this difference. However, a contribution to driver counts from 
allosomes is to be expected and this would be an interesting further extension of the current study.
We eschew a comparison with other such classifiers in the discussion below because in Rogers et al.18 we 
established an improved performance of CScape against MutationAssessor (MAS)13, PolyPhen211, SIFT12, 
FATHMM-MKL7, CADD14, DANN15 and FunSeq220. During the training process CScape could use up to 30 
feature groups which may be informative about disease-driver status, though will typically use only a subset of 
these which are found to be informative (these subsets are different for prediction in coding and non-coding 
regions). The classifier used some feature groups from the Variant Effect Predictor21 representing allele conse-
quences and affect on amino acids. For positives (disease-drivers, drawn from COSMIC19), we used a filtering 
threshold based on the highest recurrence level for a SNV observed in the COSMIC data which shows little 
evidence of bias and provides enough training examples to build a classifier. With this criterion we selected a 
recurrence threshold of r = 5 in coding regions and r = 3 in non-coding regions18. The classifier was tested using 
leave-one-chromosome-out cross-validation (LOCO-CV) in addition to being tested on previously unseen data 
from four datasets covering single point mutations in coding regions of the cancer genome, and two datasets 
covering mutations in the non-coding regions of the cancer genome. Using balanced test sets, and LOCO-CV 
testing, the classifier could achieve a test accuracy of 72.3% in coding regions and 62.3% in non-coding regions 
with some higher test accuracies on independent datasets. A confidence measure was associated with the pre-
dicted class label (disease-driver or neutral), denoted as a p- score18. This score was determined by Platt scaling22 
and is on a range 0 to 1 (0 is maximum confidence of negative and 1 of positive). As one would expect, the test 
accuracy on high confidence predictions is higher than these baseline test accuracies, 72.3% and 62.3%, based on 
a 0.5 threshold on the p-score. With high confidence prediction, for example, we achieve a balanced test accuracy 
of 91.7% in coding regions and 76.1% in non-coding regions at p-score thresholds of 0.89 (coding) and 0.70 
(non-coding) respectively. The positive predictive values (PPV) and numbers of true positives predicted indicate 
balanced predictive accuracy rather than a misleading test accuracy based on accurate inference with one class 
only (e.g. the negatives).
CScape predictions are available as an online resource http://cscape.biocompute.org.uk. A predictions data-
base, software for querying the database and training and test datasets are all available for download from this 
website.
Results
Motivation for the study. We applied the CScape predictor to a variety of common solid tumour cancers 
to determine the mean and median number of SNV-drivers in coding regions of the cancer genome. We found 
a reasonable alignment with Martincorena et al.6 using test data derived from the International Cancer Genome 
consortium23 and labelled as primary tumours. To compare the means and medians of different types of cancer 
we will initially use samples which are not differentiated by stage of disease. However, we discuss the influence of 
stage of disease later in this Section, in the Discussion and the Supplementary.
With this assumption, and comparing means for cancer types in common between both analyses, we find that 
our lowest and third lowest ranked cancers by SNV-driver count are thyroid and renal cancer and these are lowest 
ranked by Martincorena et al.6. Martincorena et al.6 give bladder urothelial, uterine corpus endometrial and eso-
phageal cancers as having the highest counts, for the means, and these are highest, third highest, and fifth highest 
for CScape, across the cancer types they consider. Breast cancer is an example of a cancer with a SNV-driver count 
towards the lower end of the range, with a mean of 6 coding drivers and Martincorena et al.6 similarly state a low 
mean of 4 coding driver mutations for this disease. Illustrative plots for thyroid and breast cancer are given in 
Supplementary Fig. 1, and a comparison across a variety of cancer types in Supplementary Fig. 2, all at the same 
value of the p-score threshold (0.9). However, we note that the choice of the p-score threshold influences the stated 
counts (cf. Supplementary Fig. 1): with a lower threshold on the confidence we let through more prospective posi-
tives and increase the count. This approximate agreement on the limited numbers of drivers involved, and the rel-
ative ranking of common solid tumours, is achieved despite the methodologies being quite distinct: CScape uses 
training data from two different sources, cancer data from COSMIC19 and data from the 1000 Genomes Project10, 
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derived from healthy subjects. The test data used in the study below was derived from the International Cancer 
Genome consortium (ICGC23, cf. Supplementary Section 1). In contrast, Martincorena et al.6 use data derived 
from 7,664 tumours from The Cancer Genome Atlas24 (TCGA). CScape is based on an integrative binary classifier 
using a wide range of feature groups, while Martincorena et al.6 propose a statistical argument based on the dN/
dS ratio. A small number of features used by CScape use data from the Variant Effect Predictor (VEP21) and are 
thus influenced by prospective amino acid substitution. The advantages of using an integrative machine learning 
classifier over an argument based on dN/dS, is that the classifier is able to predict which single point mutations 
are drivers, with an associated confidence score, the method implicitly uses a wide variety of data sources for this 
prediction and the method can be adapted to make predictions of the driver status of single point mutations in 
non-coding regions. In this study we removed samples with apparent hypermutation (more than 500 drivers), and 
a description of the data and method is presented in Supplementary Section 1.
Estimations using a false discovery rate of 5%. Given this motivating observation, in this paper we 
investigate disease-driver mutation counts, for single point mutations, across the genomes of a number of types 
of common solid tumour. We have noted that these mutation counts will be dependent on the selected threshold 
on the p-score. Determination of a significant threshold on a range of p-values is a well studied issue in many bio-
medical contexts. For example, with the analysis of expression array data, a spectrum of p-values is often obtained 
in an experimental context and the size of the set of differentially expressed genes is very dependent on the 
p-value threshold. Following discussion of the most suitable approach to threshold determination in the statistics 
literature25,26, our first approach would be to use the false discovery rate (FDR), as our criterion. In Fig. 1 (top 
row) we give the proportion of correct positive and negative predictions on test data for the two sub-classifiers 
within CScape (CS-coding and CS-noncoding for prediction in coding and non-coding regions respectively, see 
Rogers et al.18). Whereas CS-coding could be viewed as reasonably successful overall and apparently accurate with 
high confidence prediction, CS-noncoding is weak overall because of our current lack of understanding of the 
pathogenic impact of variants within non-coding regions of the cancer genome. From a statistical viewpoint and 
using balanced test data, we can use integrated proportions beyond a given threshold value from these histograms 
as a proxy for true and false predictions, and hence we can estimate a FDR for a given threshold on the p-score 
(Fig. 1). With this first attempt we will use a conservative FDR of 5%. This criterion gives threshold values of 0.88 
(coding) and 0.68 (non-coding). Given this choice for the FDR, in Fig. 2 we give the modes, mean and median 
numbers of SNV-drivers in coding regions of the genome, across a number of types of cancers. Thyroid cancer 
has a very low median for the SNV-driver count and the cancer with the highest median is bladder urothelial 
cancer. Some of these results are consistent with our understanding of distinct cancer types. For example, samples 
Figure 1. Top, left: the proportions (y-axis) for prediction of positives (disease-drivers) and negatives (neutral) 
at different values of the p-score threshold (x-axis), for predictions in coding regions of the cancer genome. Top, 
right: the proportions (y-axis) for prediction of positives (disease-drivers) and negatives (neutral) at different 
values for the p-score threshold (x-axis), for predictions in non-coding regions of the cancer genome. Bottom, 
left: The False Discovery rate (FDR, y-axis) versus the threshold on the p-score (x-axis) for prediction in coding 
regions. Bottom, right: The False Discovery rate (FDR, y-axis) versus the threshold on the p-score (x-axis) for 
prediction in non-coding regions.
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associated with skin cutaneous melanoma exhibit a large difference between the mode and median suggesting an 
extensive heterogeneity which could arise from an abundance of single point mutations induced by ultraviolet 
(UV) sunlight exposure.
Mutations driving cancer are typically random in occurrence and the mode of the distribution could be 
expected to lie at a lower SNV count than the median, as would be the case for a Poissonian distribution (except-
ing hypermutation, relatively fewer numbers of examples are observed with relatively larger mutation counts). 
Given the existence of subtypes of various categories of common solid tumour, this distribution of counts is likely 
multi-modal in general. In Fig. 2 we plot the primary mode (the highest peak in a histogram) and the median 
across a number of common solid tumour types. As expected, the mode is generally lower than the median. This 
observation suggests that there are potentially significant numbers of patient tumours with smaller driver sets 
than suggested by the medians we have presented (we call these neo-modal populations).
estimations independent of the p-score threshold. We can also gain useful insights which are inde-
pendent of our criterion for choosing a FDR or p-score threshold. Firstly, in Fig. 3, we give the medians for a 
selection of common solid tumours plotted across a range of p-score threshold values. Further plots are presented 
in Supplementary Section 3 covering a broader range of cancers, in addition to considering the mean counts. 
The given curves do not typically cross each other so the relative ranking of different types of cancer, according 
to SNV-driver count, is preserved and largely independent of the p-score threshold used. We consistently find 
that thyroid cancer has a very low SNV-driver median count and bladder urothelial cancer has the highest. We 
may use the non-parametric two-sided Mann-Whitney U test to determine the p-value for the hypothesis that 
the SNV-driver count sets are representative of the distribution across all types of cancer rather than forming 
a distinct population for the given cancer type. The sample sizes per cancer type are generally large in number 
(Supplementary Table 1, 528 samples for thyroid cancer, for example) and differences between medians and 
means quite large. Thus, as expected, these p-values are statistically significant. Taken against the reference of the 
whole population across all cancers, but excluding the given cancer type, the p-value for thyroid cancer is upper 
bounded by 10−100, for example, for a calculation based on a FDR of 5%. Thus this differentiation for SNV-driver 
counts between different types of cancer is very significant.
Secondly, we can also acquire a basic estimate of the SNV-driver count which is independent of a choice of 
FDR or threshold on the p-score. For a variant at position i and a given mutation (e.g. A → C), let ci = +1 denote 
classifier predicts a driver, ni = +1 denotes it is a driver. Similarly, ci = −1 denotes neutral prediction, and ni = −1 
denotes the variant is neutral. As before, for prediction in coding regions, we can use the relative proportions 
in a bin (cf. Fig. 1) to estimate p(ni = +1|ci = +1) and p(ni = −1|ci = +1), thus using the test data as a proxy for 
believing ni = +1 or ni = −1 and noting that these prediction counts have been derived from 50:50 balanced test 
data. We include a contribution to the count when p(ni = +1|ci = +1) > p(ni = −1|ci = +1) i.e. for a given muta-
tion at position i, the classifier would more likely correctly predict a variant would a driver, rather than neutral. 
Assuming this eligibility for inclusion in the count, if a p-score falls within a given bin in the histogram then its 
contribution to the count is (+1)p(ni = +1|ci = +1) + (−1)p(ni = −1|ci = +1) and we integrate these weighted 
predictions. This allows for the inclusion of less confident estimations of disease-driver status, though weighted 
by the factor that these predictions may, indeed, be false positives. We sum up the counts this way and the corre-
sponding modes, means and medians across a variety of common solid tumours are given in Fig. 4. As expected, 
the means and medians for the SNV-driver counts increase over the more conservative results in Fig. 2. Due to 
the different distribution and estimation of the primary mode relative to Fig. 2, the modes are still frequently low. 
Figure 2. The estimated modes (blue), the medians (red) and the means (green) for coding SNV-drivers across 
a variety of common solid tumours. A few circles are other colours due to a co-incidence of these statistical 
measures. These results were generated using a false discovery rate of 5%, leading to a threshold of 0.88 on the 
p-score.
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However, even with this less conservative estimation method, the number of SNV-drivers remains low and in the 
region of double digits at most.
The influence of stage of disease. So far, in order to compare different types of cancer, we have amalga-
mated samples for a given type, independently of stage of disease. In Supplementary Section 4 we tabulate the 
means and quartiles for SNV-driver frequency counts predicted by CScape, where the cancer has been strati-
fied by stage of disease. The prospective accumulation of SNV-driver mutations with stage of disease has been 
argued by many authors, though frequently via observation of tumour mutational burden (TMB), the number of 
non-synonymous mutations in coding regions of the cancer genome. We can also define an estimated tumour 
driver burden (TDB), as the number of estimated drivers in coding regions. Since many non-synonymous muta-
tions are not disease-drivers, the TDB is obviously more insightful, but requires a method to separate passengers 
and drivers. The paper of Martincorena et al.6 attempts such a distinction and they include a study (p. 1036 of 6 
and their Fig. S4C) to evaluate whether the number of driver mutations significantly increases as cancers pro-
gress. This is achieved via driver estimates for stage I and stage IV tumours. Interestingly, they find no significant 
differences in the number of estimated drivers. Our results presented in Supplementary Section 4 are in general 
Figure 3. Plots of the medians across a range of common solid tumours for the counts of disease-driver SNVs 
in coding regions of the cancer genome. The y-axis gives the median count of disease-driver single point 
mutations, the x-axis gives the p-score threshold. Plots covering a wider variety of common solid tumours or 
using the mean counts instead are presented in Supplementary Section 3.
Figure 4. The estimated modes (blue), the medians (red) and the means (green) for coding SNV-drivers across 
a variety of common solid tumours. These results do not depend on a choice of the FDR or p-score threshold. 
In this estimation we have used histogram bins of size 0.01 for the p-scores with normalisation of counts within 
each such bin to provide estimates of p(ni = +1|ci = +1) and p(ni = −1|ci = +1).
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agreement with this observation. Thyroid (typecode: THCA) and renal cell (RECA) cancers have low TDBs which 
remain approximately constant with stage. Similarly, esophagal (ESCA) and gastric cancer (GACA) do not appear 
to accumulate drivers with stage of disease. Cancers in our analysis, not covered in6, and also with no evidence 
of accumulation of drivers with stage, are malignant lymphoma (MALY), pancreatic cancer (PACA) and neuro-
blastoma (NBL). The latter has a very low TDB which remains static according to stage. Possible exceptions to 
this picture are colorectal (COCA) and liver cancer (LICA) which may demonstrate increasing TDB with stage, 
according to our analysis. We observe a consistent monotonic accumulation of SNV-drivers with stage of disease 
for prostate cancer (both EOPC and PRAD). Hence, accumulation of SNV-drivers with stage of disease appears 
as an exception, across different types of cancer, rather than a general trend.
Genes acting as disease-drivers. An interesting further question is the identification of those genes where 
these SNV-drivers are commonly located. As a machine learning based method, a requisite starting point will be 
demonstrated validation of the method on unseen test data. Hence we start by illustrating classifier performance 
on the top 50 identified prospective SNV-drivers reported in the comprehensive study of Rheinbay et al.27, where 
we select coding drivers, non-coding drivers will be considered later. This study used data from the ICGC and 
TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium, giving a dataset of more than 2,700 
cancer genomes derived from more than 2,500 patients. Since CScape was trained on cancer-specific COSMIC 
data19, and 1000 Genomes10 for the healthy controls, the PCAWG dataset acts as an independent evaluation. The 
confidence measures for CScape prediction are presented in Table 1 with a restriction to coding SNV-drivers in 
the autosomes of cancer genomes. One of the most common SNV-drivers is in the gene KRAS which expresses 
the K-Ras protein. This protein functions in the RAS/MAPK pathway which is hyper-activated in up to 30% of all 
cancers28. NRAS is another member of the RAS subfamily, inclusive of HRAS and KRAS, and has been implicated 
in many human cancers29. The involvement of the PIK3CA gene in a wide variety of common human cancers has 
been well supported by many studies30. Somatic mutations in the well-known tumour suppressor gene TP53 are 
one of the most frequent alterations in human cancers31. Finally IDH1 is an example of a gene with more spe-
cific effects in certain types of cancer. Thus somatically acquired mutations have been implicated in gliomas and 
chondrosarcomas32. Excepting TP53, CScape predicts that all these single point mutations are disease drivers with 
confidence levels equal to, or exceeding, 0.829. TP53 is different in that any alteration at some locations will act as 
a disease-driver (e.g. 17:7577538). However, at other locations, the type of alteration involved is important. Thus, 
at 17:7577094, G → A is a predicted oncogenic driver and G → T is predicted benign.
In terms of the broader set of cancer genes implicated by CScape, we note that the classifier was trained 
on assumed SNV-drivers derived from the COSMIC database. Observed recurrent somatic point mutations 
restricted to cancer samples will act as positives in the training data and will therefore largely reside in genes 
already documented in the COSMIC Cancer Gene Census33. As a machine-learning based tool, however, CScape 
will be able to generalize and make predictions to unseen examples not in its training set. An example would be 
the gene PRKCA. A recurrent point mutation at chromosome 17, position 64738741 G → C, introduces a D463H 
amino acid substitution and this has been described as a hallmark of chordoid glioma34. The authors of the rele-
vant study34 comment that a query of the COSMIC and cBioPortal databases found no PRKCAD463H mutation 
referenced and this gene is not currently (2019) in the COSMIC Cancer Gene Census. However, CScape (GRCh37 
reference) predicts this point mutation as oncogenic with high confidence (0.964).
Gene Chr. Position Ref. Mut. Confidences
KRAS 12 25398284 C {A, G, T} {0.922, 0.916, 0.910}
KRAS 12 25398285 C {A, G, T} {0.931, 0.915, 0.902}
PIK3CA 3 178952085 A {C, G, T} {0.854, 0.804, 0.829}
PIK3CA 3 178936091 G {A, C, T} {0.959, 0.949, 0.991}
TP53 17 7577120 C {A, G, T} {0.887, 0.920, 0.876}
TP53 17 7577538 C {A, G, T} {0.932, 0.951, 0.909}
TP53 17 7577094 G {A, C, T} {0.819, 0.853, 0.322}
TP53 17 7578212 G {A, C, T} {0.989, 0.854, 0.443}
TP53 17 7578190 T {A, C, G} {0.926, 0.916, 0.915}
TP53 17 7577539 G {A, C, T} {0.877, 0.907, 0.459}
TP53 17 7577121 G {A, C, T} {0.760, 0.875, 0.717}
NRAS 1 115256530 G {A, C, T} {0.987, 0.911, 0.931}
IDH1 2 209113112 C {A, G, T} {0.940, 0.957, 0.926}
Table 1. The top recurring single point driver mutations in coding regions proposed by Rheinbay et al.  
(Extended Data Fig. 1 in27). Their study uses data from the Pan-Cancer Analysis of Whole Genomes 
Consortium and uses in excess of 2,700 cancer genomes from more than 2,500 patients. This table only gives 
single nucleotide variants located on autosomes and labelled by our classifier as residing in coding regions (the 
corresponding table for non-coding mutations is presented in Supplementary Section 6). The table presents the 
gene, chromosome (Chr.), position and reference nucleotide (Ref.) based on the GRCh37 reference genome. 
The three prospective variants are presented (Mut.) with the confidence driver-status given in the next column, 
in the same relative order, and derived from our predictor CScape (http://cscape.biocompute.org.uk).
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Using CScape we can also choose a particular cancer and rank genes according to the relative frequency of 
occurrence of SNV-drivers. As an example, suppose we select pancreatic cancer and, using ICGC data, we rank 
genes according to the percentage of samples which have at least one SNV-driver predicted with a confidence 
(p-score) equal to or exceeding 0.88 (hence associated with a false discovery rate of 5% or less). We find the 
top ranked gene is KRAS (incidence of 86.5%), followed by TP53 (41.0%), SMAD4 (12.9%), TTN (6.3%) and 
TNN-AS1 (5.8%). The role of KRAS in pancreatic cancer is well documented35. The requirement of a minimum 
of one such high confidence SNV-driver may appear low, but we have been arguing that there are a very small 
number of such SNV-drivers in a typical cancer genome. Hence a frequency count taken across multiple samples, 
with this criterion, will highlight significant driver-genes by type of cancer.
A listing of the top five genes containing at least one of these high confidence SNV-drivers is presented in 
Table 4 to 8 of the Supplementary, across 25 types of cancer (the full listing is at36). Most of the listed genes are 
well known in their respective contexts. Though the percentages differ by type of cancer, TP53 manages to qual-
ify in the top five genes for 17 of 25 types of cancer. Other genes which feature across multiple types of cancer 
and enter the top five driver-gene list are PIK3CA (in 6), KRAS (in 5) and CTC-297N7.11 (in 4). APC37 appears 
as the top ranked driver gene for colon adenocarcinoma (COAD) and colorectal (COCA) cancer and the genes 
and comparative ranking of all top five genes is the same between these two (despite usage of different tumour 
samples). BRAF also qualifies in the top five cancer genes in two instances: skin cutaneous melanoma and thyroid 
cancer. Mutations in BRAF are well known and studied in the context of melanoma38. Thyroid cancer has these 
types of SNV-drivers present in BRAF in 55.8% of cases, the next qualifying genes being TTN, TTN-AS1, NRAS 
and KMT2C all with a low incidence rate of 1.3%. The relevance of BRAF in thyroid cancer has been noted by a 
large number of authors e.g.39.
Several genes are highly mutated but are usually excluded from candidate cancer driver lists40. These genes are 
mostly extremely large and they include Titin (TTN), the gel forming mucins (MUC) and ryanodine receptors 
(RYR)41. Apart from size, which increases the probability of accumulating false positive predictions, argument is 
weighted against giving TTN driver status since it is commonly mutated in non-cancer tissue42 and expression 
is restricted to muscle protein formation, among other issues. However, TTN is a complex gene and it co-occurs 
in our lists with TTN antisense RNA 1 (TTN-AS1), the latter pairing with TTN, at an equal, or slightly reduced 
frequency of occurrence. TTN-AS1 is a long non-coding RNA gene which is transcribed from the opposite strand 
to the Titin gene. TTN mutations have been reported as highly predictive of patient survival with some cancers41 
and TTN-AS1 has been recently argued as an oncogene across several cancers43–46.
The above mentioned driver-genes are generally well studied in cancer research and are typically highly 
ranked using methods based on a count of observed non-synonymous single point mutations across cancer 
genomes. However, the percentage occurrence of mutations in genes tends to tail rapidly and it is in this tail of 
low incidence rates for given SNVs where CScape can be most useful in distinguishing passengers from drivers. 
On the Help/Documentation webpage of the CScape website36 we present a longer list of ranked genes (file: 
driver-genes) detailing these tails of driver-genes across the 25 types of cancer considered here, using the same 
FDR of 5%. In Rogers et al.18 we also investigate contiguous nucleotide sequences of high confidence predictions 
for driver-status (called Regions of Interest). This study highlighted 191 autosomal genes, much less studied in the 
cancer literature and not typically marked by common mutations.
Apart from selecting a cancer type and ranking genes within the type, the other way of portraying data is to 
select a gene and estimate its influence as a driver-gene across different cancer types. In Fig. 5 we portray the per-
centage incidence for having at least one SNV-driver, at a false discovery rate of 5%, for the genes TP53 and KRAS 
across 25 cancers, as an illustration.
Drivers in non-coding regions of the cancer genome. As commented in the beginning, for non-cancer 
disease, the ratio of documented SNV-drivers in non-coding regions over coding regions, suggests the large 
majority of SNV-drivers are located in non-coding regions. Some studies have argued that cancer genomes do not 
follow this trend and that the ratio of drivers in non-coding regions to coding is relatively smaller27. We do not 
regard CScape predictions in non-coding regions of the cancer genome as reliable enough to suggest a resolution 
of this issue (Fig. 1, top right subfigure). However, there are a number of single-point mutations in non-coding 
regions which have been verified as disease-drivers and useful insight will be gained from considering these. As 
we have previously discussed18, three mutations in the TERT promoter region have been characterised as disrup-
tive to putative ETS (E26 transformation specific) family transcription factor binding sites47–49 and are verified 
drivers. Five additional recurrent driver mutations in regulatory elements upstream of SDHD and PLEKHS1 have 
been documented49. CScape correctly predicts 7 from 8 of these mutations as putative drivers18 with confidence 
measures in the range 0.52 to 0.81. The exception is one mutation for SDHD which is outside the core response 
element. This performance is only matched by DANN for the methods used in our comparison18.
We have extended this analysis to the larger set of non-coding SNV-drivers proposed in the Pan-Cancer 
Analysis of Whole Genomes (PCAWG) study of Rheinbay et al. (cf. Extended Data Fig. 1 in27). We use their 
top 50 list of proposed coding and non-coding SNV-drivers, restricting to autosomes and locations which our 
predictor labels as non-coding. The results are tabulated in Supplementary Table 9. Of the 31 non-coding loca-
tions considered, 23 point mutations are predicted oncogenic by CScape. At 7 further locations the prediction is 
labelled possibly oncogenic, that is, the predicted driver status label is oncogenic or benign depending on the type 
of mutation which has occurred. Only in one instance is the predicted label benign (1:10359944). This is a good 
level of prediction performance, noting that CScape was originally trained and tested on approximately balanced 
datasets in terms of class label18, and therefore does not have an implicit bias towards positive, disease-driver, 
prediction. However, for those point mutations where the prediction is oncogenic, covering the three possible 
alterations, 64 lie in the confidence band of 0.5 → 0.7 and 19 have a confidence greater than 0.7. The implication 
is that the large majority of non-coding oncogenic predictions lie in regions of weak confidence for the classifier 
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(Fig. 1, top right subfigure). This allows for substantial numbers of false positives and false negatives and therefore 
a high expected variance in the frequency count of SNV-drivers in non-coding regions. Any restriction to using 
a reasonable confidence level for oncogenic status could lead to misleading under-estimation. Applied to cancer 
genomes, CScape often makes other positive predictions in the confidence band 0.5 → 0.7 beyond the sites given 
in Supplementary Table 9, and this leaves open the prospect of further non-coding drivers. Thus, an accurate 
estimate of the frequency count of SNV-drivers in non-coding regions awaits the development of more accurate 
predictors in non-coding regions, possibly specific to the functional structures lying in these regions.
Discussion
Though SNV-driver sets appear small in size, various factors could lead to under-estimation of the driver count 
or create problems with interpretation. The CScape classifier was trained on assumed positives observed to have 
a high recurrence among a large number of tumours (r ≥ 5 in coding regions and r ≥ 3 in non-coding regions) 
while being absent from the neutral control samples. However, a tumour suppressor gene, for example, could 
be inactivated by SNVs scattered at very low recurrence rates per nucleotide position across a genomic region, 
such as an exon. Though functionally active in disease, the low frequency of occurrence of such variants means 
that they would be labelled negative (neutral) in both training and test sets. This shortfall in estimation can 
only be addressed with larger datasets and improved methodology for more accurately determining, potentially 
region-variable, recurrence levels for the labelling of a variant as a disease-driver.
There is also a potential bias leading to over-estimation of the SNV-driver count. In order to avoid bias, the 
CScape classifier was trained on approximately balanced data, in terms of positive disease-drivers and negative 
neutrals. This means that the number of false positive and false negative predictions should be approximately 
balanced. Evidently, the number of positive disease-driver SNVs is very small and this could lead to a bias towards 
over-estimation. We can understand this type of bias with an invented example. Thus, suppose we have an illustra-
tive dataset with only 0.001% positives, the rest labelled negative. A predictor with very limited test accuracy, but 
balanced for false positives and false negatives, would predict approximately half the test datapoints as positives, 
even if these are with very low confidence. This bias explains the rising median estimates with lower p-score 
thresholds, portrayed in Fig. 3, for example. With a lower threshold on the p-score, we allow for more errors and 
therefore more false positives. Unfortunately, this type of bias can only be fully removed by the development of a 
classifier which is totally accurate on all test data.
Bias created by dependence of SNV-driver set sizes on the p-score cutoffs has also been an issue we discussed. 
In the Results Section we partly answer this issue with presentation of results independent of a threshold choice. 
We can also restrict to a false discovery rate of 5%. Relative to some other approaches, for example, Martincorena 
et al.6, our method has advantages of direct estimation by identification of SNV-drivers, together with inde-
pendent validation of the methodology on unseen test data. However, this issue is a drawback and raises the 
consideration of possible further models which may fix a threshold with reduced ambiguity, while also pro-
spectively identifying those variants driving disease. Such strategies would be possible, if an alternative criterion 
becomes available which is viewed as more accurate, but gives only genome-wide or gene-level estimations of 
driver counts. For example, suppose we wish to conform with the dN/dS argument of Martincorena et al.6. In 
this case one would minimise an objective function consisting of the sum of the absolute differences (or squared 
errors) between the predicted driver counts per gene and their number of driver mutations predicted per gene 
derived from dN/dS. This can be achieved by iteratively pursuing a one-dimensional line search for the optimal 
p-score cutoff threshold. This threshold could be cancer-type specific but would provide predictions of actual 
driver mutations in concordance with such an alternative model.
Our analysis of SNV-driver frequency counts by stage of disease also covered a different possible source of 
bias. Cancers can be initially detected at different stages of the disease, on the average, and successful intervention 
may reduce the population of late stage disease, which is therefore not fully represented. This leads to different 
sample sizes for different stages of disease (Supplementary Section 4) which in turn creates a possible bias in 
the use of a stage-independent mean frequency count comparison across different types of cancer. Our study 
Figure 5. The percentage incidence (y-axis) for the selected gene having at least one SNV-driver, determined 
with a false discovery rate of 5% for Left: TP53, Right: KRAS. Data is from the International Cancer Genome 
Consortium and the x-axis gives the typecode for the given type of cancer (see Supplementary Table 1).
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indicated that for some types of cancer there is further accumulation of SNV-drivers as the disease progresses. 
However, for the large majority of cancer types, our study was in general alignment with Martincorena et al.6, in 
suggesting very limited accumulation of further SNV-drivers as the disease progresses through stages. For these 
cancer types, stage-independent estimation is therefore sound. Cancers where stage has an influence on driver 
count may be liver cancer and colorectal cancer with apparent rising SNV-driver counts by stage. For colorectal 
cancer this may conform with multi-step models for this disease1. Allowing for this rising trend, bladder urothe-
lial cancer may not be particularly exceptional for a high driver count (Supplementary Section 4). For example, 
Figs 2 and 4 suggest prostate cancer (EOPC and PRAD) has low SNV-driver set sizes. However, for late onset 
disease (PRAD), there is a suggestion in the data (Supplementary Section 4) that stage IV prostate cancer may 
have larger coding SNV-driver sets sizes than bladder urothelial cancer (BLCA): it is just that the acquisition of 
prostate cancer data (PRAD) has been dominated by stage II tumour samples.
conclusion
Despite these various possible biases affecting driver count estimation, a number of insights appear sound. Firstly, 
some types of cancer have exceptionally low mean counts for the numbers of coding SNV-drivers, at levels which 
are very statistically significant. This observation can be applied to thyroid cancer, neuroblastoma and renal can-
cer, and there appears little further accumulation of SNV-drivers as these cancers progress to later stages of dis-
ease. Thyroid cancer was particularly remarkable with its low driver count and substantial influence of the gene 
BRAF as a driver. As expected, there are very statistically significant differences between driver counts for individ-
ual genes, for a given type of cancer, and in the prominence of a gene across different types of cancer.
Secondly, the above analysis supports the general message proposed by other groups4,6,27, that the mean num-
ber of coding SNV-drivers for most cancers is typically very small in size, either single digits or low double digits. 
Even for those cancer types where the mean size of coding SNV-driver sets is larger (double digits), there exist 
significant populations of tumours where, again, the coding SNV-driver set size is small and commonly back in 
the region of single digits (the neo-modal signatures discussed earlier). This observation is accentuated by our 
preceding discussion of an over-estimation bias stemming from the use of a partially accurate balanced classifier 
for estimation where one class (here, the positives) is very small in relative size. Taking note of this latter obser-
vation, the actual SNV-driver set sizes could be very small indeed, prospectively single digits on the average 
(excluding hypermutation), a view argued by authors cited in the Introduction.
The third observation is that machine learning methods, e.g. CScape, can be partially successful in identifying 
members of these driver sets (cf. Table 1 and Supplementary Table 9). The indicated low driver set sizes, and the 
ability to partially identify members of these small sets, suggests an ability to identify many of the core variants in 
the cancer genome which drive the development of a particular tumour.
The fourth observation is that these are machine learning methods under discussion and, as such, they can 
generalize. In the Introduction we mentioned 72.3% (coding) and 62.3% (non-coding) balanced test accuracies 
for CScape. In this case we remove any training examples which may have entered the test set, and evaluate test 
accuracy on this filtered set. For zero training error, the re-presentation of a training example to the CScape clas-
sifier will lead to correct categorisation, resulting in a positive selection for correct prediction. Highly recurrent 
positive point mutations within the COSMIC database will also likely feature as highly recurrent point mutations 
in the PCAWG data discussed earlier and hence not all examples within the PCAWG dataset may effectively qual-
ify as unseen to the classifier. Even if the PCAWG dataset is new to the classifier, this explains the strong reported 
performances in Table 1 and Supplementary Table 9. However, the classifier is also able to generalize to unseen 
instances with a non-trivial accuracy. This observation becomes important when we note that our study of cancer 
genes in the Results Section, highlighted a number of well known driver-genes (TP53, KRAS, BRAF, etc) together 
with long tails of infrequent drivers36 which are most likely unique to an individual tumour and patient. It is in 
these tails of previously unseen instances where the classifier would be able to correctly label driver-status with 
some degree of accuracy.
The above study can be extended in many directions. One obvious choice is to pursue a parallel study of indel 
frequency counts across different types of cancer. Thus, for neuroblastoma, for example, our analysis suggests 
that single point driver mutations barely play a role and other categories of driver must be relevant. Indels are 
more substantial alterations to the genome, relative to SNVs, and predictors proposed in this context, e.g.50, have 
accordingly higher test accuracy. Another direction highlighted by our discussion has been the necessity to create 
improved predictors for SNVs in non-coding regions of the cancer genome. Other areas for investigation would 
be the role of intra-tumour heterogeneity, investigating additional SNV-driver contributions from the allosomes 
and the differences between identified subtypes of cancer e.g. breast cancer has clinically relevant subtypes51 and 
sub-stratification of driver-counts would be expected.
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